PAIN: A Project Assessing the Impact of a Novel Cannabinoid Product

Description

This study is a clinical trial of a high-cannabidiol (CBD) sublingual product compared to placebo for 9 weeks in patients with chronic pain conditions. The study will assess the impact of CBD on chronic pain symptoms, conventional medication use, clinical state, quality of life, cognition, and biomarkers.

Conditions

Chronic Pain

Talk to us

Study Overview

On this page

Study Details

Study overview

This study is a clinical trial of a high-cannabidiol (CBD) sublingual product compared to placebo for 9 weeks in patients with chronic pain conditions. The study will assess the impact of CBD on chronic pain symptoms, conventional medication use, clinical state, quality of life, cognition, and biomarkers.

PAIN: A Project Assessing the Impact of a Novel Cannabinoid Product

PAIN: A Project Assessing the Impact of a Novel Cannabinoid Product

Condition
Chronic Pain
Intervention / Treatment

-

Contacts and Locations

Belmont

McLean Hospital, Belmont, Massachusetts, United States, 02478

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Subject has provided informed consent
  • * Subject is 21 or older
  • * Subject is fluent in English
  • * Subject endorses a chronic pain condition including, but not limited to, chronic pain due to injury, musculoskeletal pain, arthritis (including osteoarthritis and rheumatoid arthritis), fibromyalgia, bursitis, endometriosis, etc.
  • * Non-fluent English speakers
  • * Estimated IQ \< 75
  • * A history of head injury or loss of consciousness greater than 5 minutes
  • * Currently uses CBD products regularly
  • * Female subjects will be excluded if they have a positive urine pregnancy test, are trying to become pregnant, or are currently breastfeeding
  • * Presence of a serious or unstable medical illness, including liver, kidney, or cardiovascular disease (hyper/hypotension, cardiac disorders), or neurological disorder (including seizure disorder)
  • * Neuropathic pain or cancer-related pain
  • * Disclosure of a genetic polymorphism affecting CYP2C9 function

Ages Eligible for Study

21 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Staci Gruber, Ph.D.,

Staci Gruber, Ph.D., PRINCIPAL_INVESTIGATOR, Mclean Hospital

Study Record Dates

2026-09